Resmetirom is an investigational oral medication aimed at reducing the symptoms and reversing the effects of Non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease. The medication is delivered to the liver and selectively acts to activate a thyroid hormone receptor, THR-β. This is underexpressed in patients with NASH. Clinical trials for this groundbreaking medication were performed at multiple ENCORE Research Group member sites, including Jacksonville Center for Clinical Research, Nature Coast Clinical Research, and St. Johns Center for Clinical Research. Trials remain ongoing throughout the country and we are excited to see resmetirom continue through the clinical trials process.

Watch a news interview about it here: